Navigation Links
Evista Not A Cure For Heart Disease

Evista is the market name of the drug raloxifene HCl is manufactured by drug maker Eli Lilly & Co. a study was conducted which showed that Evista// , a drug used to treat osteoporosis in women, did not prevent heart attacks. The study analyzed 10,000 women in 26 countries for a period of seven years. It was studied whether if this drug given daily for the study period would lower the risks of heart attack and breast cancer in postmenopausal women who either had heart disease or were at high risk for heart attack.

Raloxifene HCl is mainly used to treat and prevent osteoporosis in postmenopausal women. But since this study proved that the drug did not prevent heart attacks the company wanted to reinforce for physicians that Evista should not be prescribed for cardioprotection. Lilly Chief Medical Officer Alan Breier said in a statement that they have gathered new data on Evista's potential to reduce the risk of invasive breast cancer in postmenopausal women. It plans to submit the details of its study to the Food and Drug Administration for review. But further analysis would be needed and precautionary measures to be taken before announcing the use of the drug with respect to breast cancer.
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Due to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Heart disease threat starts early in life for Diabetics
11. Mechanical Heart
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Evista Not Cure For Heart Disease

(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
(Date:12/26/2014)... The US represents the largest market for ... GlobalData’s forecast estimates that sales of branded therapies were $2.23 ... the high incidence of the disease, high drug treatment rate, ... China. Increased sales of CRC therapies over the forecast period ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... http://www.nhs.uk ), the,digital ,front door, to the NHS launches ... both the physical and financial cost of smoking in ... interactive calculator,( http://www.nhs.uk/Tools/Pages/Smoking.aspx ) enables users to not only ... much you could save over,one to ten years - ...
... 11 In this 90 minute episode, Dr. Drew,reunites several ... they left treatment. Drew reveals who has relapsed, who has ... is comprised of,recovering addicts and fans of the show, will ... happened over the season., (Photos: ...
... as whole grains cuts risk of cerebral infarction , , ... magnesium-rich foods such as whole grains may reduce male ... flow to the brain is blocked, a new Swedish ... Stockholm analyzed the diets and other health/lifestyle habits and ...
... March 11 Perrigo Company,(Nasdaq: PRGO ; TASE) ... U.S. Food and Drug Administration (FDA) for its Abbreviated ... The product is a topical corticosteroid indicated for the ... for the brand, Olux(R),Foam, 0.05%, were approximately $85 million ...
... 11 Verathon(R) is pleased to,announce a new ... 9400,bladder volume instrument with patent-pending NeuralHarmonics(TM),Technology. Small Child ... noninvasively on children weighing less than 60 pounds ... same instrument used for adult,patients. This enhanced BladderScan(R) ...
... German . , Malignant tumors have usually ... death, or apoptosis. Therefore, tumors are often resistant to ... forcing tumor cells to commit suicide. , This ... of the numerous molecular switches regulating the self-destruction process. ...
Cached Medicine News:Health News:Magnesium May Lower Risk for Some Strokes in Male Smokers 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 3Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 2Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 3Health News:Paradigm shift: Switch for programmed cell death promotes spread of glioblastoma 2
(Date:1/23/2015)... Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. biotechnology ... solid tumor cancers, announced today that CEO Linda Powers ... Immunotherapy Forum in Washington D.C. ... January 26 at 10:30 a.m. EST at the Grand Hyatt ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, ... agreement with KRS Global Biotechnology, Inc. for the compounding, packaging ... compounded for shipment in the United States ... approved Outsourcing Facility capable of compounding naltrexone tablets in various ...
(Date:1/23/2015)... , Jan. 23, 2015  HyGreen, Inc., a leader ... and partnership with RCA Medical, a subsidiary of Ascendis ... . Each year, hundreds of millions of ... infections as organisms are transmitted from patient to patient ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... 2007 /PRNewswire/ -- Once-daily,dosing with Otsuka's investigational ... associated with improvements,in signs and symptoms of ... receiving conventional care, without an,adverse effect on ... from the short- and long-term analyses of ...
... Stent Technology Holds Promise as,Future-Generation Treatment Option ... ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ ... the world's,first clinical trial evaluating the overall ... eluting stent platform for the,treatment of coronary ...
Cached Medicine Technology:Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent 2Abbott Announces Positive Six-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent 3
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
Medicine Products: